A successful and family-owned Company
Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. Learn more about the financial highlights, the corporate vision, the organisation, the Board of Managing Directors and the company's history as well as our engagement for scientific, cultural and environmental purposes.
Compassionate Use
Boehringer Ingelheim is committed to improving people’s health and quality of life all over the world. Our focus is on developing innovative treatments with potential for break-through developments. A fundamental part of our research and development processes are our clinical trial programs. For patients with serious, life-threatening diseases who are unable to participate in one of our clinical trials, our compassionate use programs may provide access to selected medications before completion of the full regulatory review.
-
Compassioante Use_Our Position
Compassionate Use
Boehringer Ingelheim’s position on compassionate use of investigational medications.
-
Mehdi Shahidi
Compassionate Use
Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
-
DOWNLOAD PDF (710.32 KB)
Compassionate Use_Global ContactsContacts around the world for more information on Boehringer Ingelheim’s compassionate use programs.
-
Compassioante Use Questions and Answers
Compassionate Use
Answers to common questions regarding Compassionate Use of experimental medications.
-
Compassionate Use
In compliance with our Policy on Transparency and Publication of Clinical Study Data, Boehringer Ingelheim is committed to disclosing all study results independent of outcome. Responsible sharing of de-identified clinical study data and redacted clinical documents are reported.
-